TenderlineUK
Procurement Intelligence
Search
Find a TenderAwardedContract details notice
Published 1 Aug 2025, 11:49 BST

Official UK procurement notice

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

Official notice

Authority: NHS England (Central government)·Consortium: 2 public authorities

Framework agreement2 lotsGoodsOpen procedureAbove thresholdSME suitableMax 1 lot to bidMax 1 lot per supplier
Sectors: Medical Devices & Pharma (33) Delivery: UKNorth East (UKC)North West (UKD)
+7 moreYorkshire & Humber (UKE)East Midlands (UKF)West Midlands (UKG)East of England (UKH)London (UKI)South East (UKJ)South West (UKK)
Framework ceiling (notional)£1,520,432,295total for 2 lots · framework ceiling, not attributable revenue
Submissions closed 14 Jul 2025awarded 31 Jul 2025
Awarded to Abbvie Ltd +9 more2 awards
Framework period 1 yr 6 moends 31 May 2027 · up to 31 May 2029 with extensions · starts 1 Dec 2025

What is being bought2 lots · detail below

Published requirement description

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

Offer reference number: CM/PHS/25/5728

Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.

Potential periods of call-offs under the framework agreement:

CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:

7NAT (National) 01/12/2025 to 31/05/2027 (18 months)

CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg:

NOFE: (North of England) 01/12/2025 to 31/05/2027 (18 months)

SOFE: (South of England) 01/12/2025 to 31/05/2027 (18 months)

MAE: (Midlands and East) 01/12/2025 to 31/05/2027 (18 months)

LNW: (London) 01/12/2025 to 31/05/2027 (18 months)

Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of;

  • neovascular (wet) age-related macular degeneration (AMD)
  • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
  • proliferative diabetic retinopathy (PDR)
  • visual impairment due to diabetic macular oedema (DME)
  • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy
  • vision impairment associated with chronic diabetic macular oedema, (DME)
  • visual impairment due to myopic choroidal neovascularisation (myopic CNV)
  • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease
  • inflammation of the posterior segment of the eye presenting as non-infectious uveitis
  • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye

CPV: Pharmaceutical products · Various medicinal products

How this framework works

From the published notice
Type
Open framework
Call-offs
call-offs are awarded directly to appointed suppliers, without further competition
Bids received
11 bids on the busiest of 2 lots · 15 suppliers appointed
Framework period
1 yr 6 mo · up to 3 yrs 6 mo from 1 Dec 2025
Buyer regions
UK
Supplier levy on call-offs (max %)
N/A
Who may buy through it

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

Published description of the framework

Please refer to the ITO Documents for the Operation Description.

Lots and requirements (2)Procurement structure

2 lots · all with a published value · a supplier may bid for at most 1 and win at most 1 of them
Lot #1CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:AwardedRenewal 1 yr 6 moSMEPublished value£709,529,158

CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: 7NAT (National)

Contract period: 1 Dec 2025 – 31 May 2027 (1 yr 6 mo) · up to 31 May 2029 with extensionsValue: £709,529,158 exc. VAT · £851,434,989 inc. VAT
Delivery: UKEligibility: SME eligible
Extensions: Option or options to extend (at the discretion of the Authority) up to maximum of 24 months.
33600000 Pharmaceutical products33690000 Various medicinal products
Lot #2CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aAwardedRenewal 1 yr 6 moSMEPublished value£810,903,137

CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg

Contract period: 1 Dec 2025 – 31 May 2027 (1 yr 6 mo) · up to 31 May 2029 with extensionsValue: £810,903,137 exc. VAT · £973,083,765 inc. VAT
Delivery: UKEligibility: SME eligible
Extensions: Option or options to extend (at the discretion of the Authority) up to maximum of 24 months.
33600000 Pharmaceutical products33690000 Various medicinal products

What it takes to win
i

How this buyer will score bids.

The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).

Evaluation split and conditions of participation as published; the tender pack may add more
How bids were scored
Lot distribution rule: There is no maximum number of Lots that can be awarded in Lot 1 - In Lot 2 there are 4 sub-lots - suppliers can be awarded only one sub-lot (subject to the number of bidders - see tender pack for further details)
What this means for your bid
  • “NHS National Framework for Medical Retinal Vascular Treatments - 1…” is a framework: the contest is a place on its panel, not a single contract, and call-offs are awarded directly: getting appointed is the whole game.

Procedure terms & legal framework

From the official record
Procedure method
Open procedure
Legal basis
UKPGA · 2023/54 Procurement Act 2023
Procurement category
Goods
Notice status
Awarded
Procurement threshold
Above threshold (FTS publication)
Regulatory regime
Standard
Commercial structure
Framework agreement
Who may use this agreement
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Competition type
Competitive procedure
GPA / WTO covered
Yes (GPA)
Recurring procurement
Unspecified in notice
First published
1 Aug 2025, 11:49 BST
Last source update
6 Oct 2025, 12:40 BST
Award evaluation window
Submission end – 31 Jul 2025
Authority reference
C346388
FTS notice number
2025/S 000-033860
Latest notice
Contract details notice (UK7)
Classification (CPV)
Pharmaceutical productsVarious medicinal products
Delivery area
UKNorth East (UKC)North West (UKD)Yorkshire & Humber (UKE)East Midlands (UKF)West Midlands (UKG)East of England (UKH)London (UKI)
+2 moreSouth East (UKJ)South West (UKK)
Official registry OCID
ocds-h6vhtk-055064 Find a Tender

How it was run

Official notice
Run through: Atamis legacy domain (health-family.force.com) · Who buys & how to bid on Atamis
Supplier login requiredElectronic submission allowedLanguage: EN
Access & registration note: Legacy Salesforce domain still used in notices — use the current Atamis portal · this portal address is a legacy domain; the operator has migrated
Appointment period ends
14 Jul 2025, 13:00 BST
Clarification deadline
7 Jul 2025, 13:00 BST
Submission channel
Official e-sourcing portal
Electronic submission
Allowed
Accepted languages
en
Supplier levy on call-offs (max %)
call-off levy · N/A
Detailed submission instructions & authority contactsFrom official release

The procurement documents are available for unrestricted and full direct access, free of charge at health-family.force.com/s/Welcome ↗ Additional info obtained from the abovementioned address Tenders must be submitted to the abovementioned address.

Timeline

19 Jun 2025 → 1 Dec 2025 · 8 dates
  1. Tender notice published
    19 Jun 2025, 17:18 BST
  2. Clarification questions by
    7 Jul 2025, 13:00 BST
  3. Admission / appointment period endsperiod end, not a bid countdown
    14 Jul 2025, 13:00 BST
  4. Assessment summaries sent
    31 Jul 2025, 00:00 BST
  5. Award decision expected by
    31 Jul 2025, 23:59 BST
  6. Standstill ends
    13 Aug 2025, 23:59 BST
  7. Latest notice published379 days ago
    6 Oct 2025, 12:40 BST
  8. Contract starts323 days ago
    1 Dec 2025

Notice history

6 events · 2 releases on Find a Tender · since 19 Jun 2025
  1. Tender notice published
    19 Jun 2025, 17:18 BST
    UK4
  2. Tender notice published
    19 Jun 2025, 22:47 BST
    UK4
  3. Contract award notice published
    1 Aug 2025, 11:49 BST
    UK6
  4. Contract signature expected
    18 Aug 2025, 23:59 BST
    scheduled
  5. Contract details notice published
    6 Oct 2025, 12:40 BST
    UK7
  6. Buyer details updated
    6 Oct 2025, 12:40 BST
Published amendments (1)

Adding in Tender documents to this notice.

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast
Suppliers appointed 153 awards · see the list ↓
Bids received 114 from SMEs · busiest of 2 lots
Named bidders 17published on the award notice
Contracts signed 2latest 22 Sept 2025
Awarded toValueDateStatus
Lot 1 · CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:2 awards
Abbvie Ltd, Alimera SciencesSME, Bayer Plc, Biogen Idec Ltd, NOVARTIS PHARMACEUTICALS UK LIMITED, Orion Pharma UK LtdSME +4 moreLot 1 - CM/PHS/25/5728/011 Dec 2025 – 31 May 2027 · up to 31 May 2029Extensions: option or options to extend (at the discretion of the Authority) up to maximum of 24 months.£688,834,17431 Jul 2025standstill to 13 Aug 2025Standstill
Abbvie Ltd, Bayer Plc, Biogen Idec Ltd, Biosimilar Collaborations Ireland Limited, Celltrion Healthcare United Kingdom Limited, NOVARTIS PHARMACEUTICALS UK LIMITED +8 moreLot 2 - CM/PHS/25/5728/021 Dec 2025 – 31 May 2027 · up to 31 May 2029Extensions: option or options to extend (at the discretion of the Authority) up to maximum of 24 months.£782,917,97231 Jul 2025Awarded

Contracts

  • Lot 1 - CM/PHS/25/5728/01 · Abbvie Ltd, Bayer Plc, Biogen Idec Ltd, Biosimilar Collaborations Ireland Limited, Celltrion Healthcare United Kingdom Limited, NOVARTIS PHARMACEUTICALS UK LIMITED +8 more

    Signed
    22 Sept 2025
    Value
    £688,834,174
    Period
    1 Dec 2025 – 31 May 2027 · up to 31 May 2029 with extensions
    Status
    active
    Extensions
    option or options to extend (at the discretion of the Authority) up to maximum of 24 months.
    1 agreed KPI: Buffer Stock requirement
    • Buffer Stock requirement, 6 months Buffer Stock

  • Lot 2 - CM/PHS/25/5728/02

    Signed
    22 Sept 2025
    Value
    £782,917,972
    Period
    1 Dec 2025 – 31 May 2027 · up to 31 May 2029 with extensions
    Status
    active
    Extensions
    option or options to extend (at the discretion of the Authority) up to maximum of 24 months.
    1 agreed KPI: Buffer Stock
    • Buffer Stock, 6 months Buffer Stock

Bid statistics published by the authority

LotBidsSMEVCSEValid bid range
1 · CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:11final-stage tenders40—
2 · CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments a7final-stage tenders10—

Who bid

Bidders as named on the Procurement Act 2023 award notice. “Won” means the bidder holds an award on this notice.

Contracting authority & participating public bodies

2 public bodies on the notice

NHS ENGLAND

Contracting authorityPublic authority - central government GB-NHS: X24 · GB-PPON: PDPT-3135-BWWY NHS England, 7&8 Wellington Place, Leeds, Yorkshire & Humber, LS1 4APContact name, email

Framework contractors & participating bidders

30 commercial parties on the notice · 27 awarded
  • ABBVIE LTDFramework contractorGB-COH: 08004972GB-PPON: PHRQ-1133-WGCH Abbvie House Vanwall Business Park, Maidenhead, South East, SL6 4UBContact email
  • ALIMERA SCIENCES LIMITEDFramework contractorGB-COH: 08018355GB-PPON: PYCZ-7339-TCCT Form 1 Bartley Wood Business Park, Hook, South East, RG27 9XAContact email
  • AMGEN LIMITEDBidder / tendererGB-COH: 02354269GB-PPON: PDJG-8184-TCQQ 216 Cambridge Science Park, Cambridge, East of England, CB4 0WA
  • Abbvie LtdFramework contractorGB-PPON: PHRQ-1133-WGCH Abbvie House Vanwall Business Park, Maidenhead, South East, SL6 4UBContact email
  • Alimera SciencesFramework contractorGB-PPON: PYCZ-7339-TCCT Form 1 Bartley Wood Business Park, Hook, South East, RG27 9XAContact email
  • BIOGEN IDEC LIMITEDFramework contractorGB-COH: 01497267GB-PPON: PTGT-3385-PBMQ Building 5 Foundation Park, Maidenhead, South East, SL6 3UDContact email
  • BIOSIMILAR COLLABORATIONS IRELAND LIMITEDFramework contractorGB-PPON: PQQC-5869-LMVX Biocon Biologics 16 Great Queen Street, London, London, WC2B 5AHContact email
  • Bayer PlcFramework contractorGB-COH: 00935048GB-PPON: PWRY-2527-LDRY 400 South Oak Way, Reading, South East, RG26ADContact email
  • Bayer PlcFramework contractorGB-PPON: PWRY-2527-LDRY 400 South Oak Way, Reading, South East, RG2 6ADContact email
  • BiogenFramework contractorGB-PPON: PTGT-3385-PBMQ Building 5 Foundation Park, Maidenhead, South East, SL63UDContact email
Show 20 more suppliers
  • CELLTRION HEALTHCARE UNITED KINGDOM LIMITEDFramework contractorGB-COH: 11685363GB-PPON: PYQL-4248-PXXY The Charter Building, Uxbridge, London, UB8 1JGContact email
  • Celltrion Healthcare United Kingdom LimitedFramework contractorGB-PPON: PYQL-4248-PXXY Celltrion Healthcare UK Limited, The Charter Building, Charter Place, Uxbridge, London, UB8 1JGContact email
  • MDBIOLOGICS LTDFramework contractorGB-COH: 15579040GB-PPON: PMHC-1596-RTNX 71-75 Shelton Street, London, London, WC2H 9JQContact email
  • MDBIOLOGICS LTDFramework contractorGB-PPON: PMHC-1596-RTNX 71-75 Shelton Street, London, London, WC2H 9JQContact email
  • MERCURY PHARMACEUTICALS LIMITEDBidder / tendererGB-COH: 02619880GB-PPON: PHGH-5788-VVDL Dashwood House, London, London, EC2M 1QS
  • NOVARTIS PHARMACEUTICALS UK LIMITEDFramework contractorGB-COH: 00119006GB-PPON: PJTX-5182-QVLR 2nd Floor, The Westworks Building White City Place, London, London, W12 7FQContact email
  • Novartis Pharmaceuticals UK LtdFramework contractorGB-PPON: PJTX-5182-QVLR 2nd Floor, The Westworks Building White City Place, London, London, W12 7FQContact email
  • ORIFARM UK LTDBidder / tendererGB-COH: 10015046GB-PPON: PQPW-1715-PJLT Ground Floor, Suite A2 Breakspear Way, Hemel Hempstead, East of England, HP2 4TZ
  • ORION PHARMA (UK) LIMITEDFramework contractorGB-COH: 02281057GB-PPON: PJZQ-1429-ZBVY The Scalpel, 18th Floor, London, London, EC3M 7AFContact email
  • Orion Pharma (UK) LtdFramework contractorGB-PPON: PJZQ-1429-ZBVY The Scalpel, 18th Floor, London, London, EC3M 7AFContact email
  • Outlook Therapeutics, Inc.Framework contractorGB-COH: 08179857GB-PPON: PGZH-1763-NPGX 111 S. Wood Ave Unit, #100 Iselin, US, NJ 08830, USContact email
  • Outlook Therapeutics, Inc.Framework contractorGB-PPON: PGZH-1763-NPGX 3rd Floor One London Square, Cross Lanes, Guildford,, Surrey, South East, GU1 1UNContact email
  • ROCHE PRODUCTS LIMITEDFramework contractorGB-COH: 00100674GB-PPON: PXCG-4172-CHYM 6 Falcon Way, Welwyn Garden City, East of England, AL7 1TWContact email
  • Roche Products LtdFramework contractorGB-PPON: PXCG-4172-CHYM 6 Falcon Way, Welwyn Garden City, East of England, AL7 1TWContact email
  • SANDOZ LIMITEDFramework contractorGB-COH: 01547204GB-PPON: PNQL-1548-CYBZ Maxis 1, Western Road, Bracknell, South East, RG12 1RFContact email
  • SANDOZ LIMITEDFramework contractorGB-PPON: PNQL-1548-CYBZ Maxis 1, Western Road, Bracknell, South East, RG12 1RFContact email
  • TEVA UK LIMITEDFramework contractorGB-COH: 00302461GB-PPON: PWDD-6894-DXRM Ridings Point, Castleford, Yorkshire & Humber, WF10 5HXContact email
  • THORNTON & ROSS LIMITEDFramework contractorGB-COH: 00185947GB-PPON: PWYH-6892-QYNN Linthwaite Labs Manchester Road, Huddersfield, Yorkshire & Humber, HD7 5QHContact email
  • Teva UK LimitedFramework contractorGB-PPON: PWDD-6894-DXRM Ridings Point, Castleford, Yorkshire & Humber, WF10 5HXContact email
  • Thornton and Ross LtdFramework contractorGB-PPON: PWYH-6892-QYNN Linthwaite Labs Manchester Road, Huddersfield, Yorkshire & Humber, HD7 5QHContact email

Official documents & specifications (9)

Official links; attachments are not copied

Tender pack and attachments

Notices published for this procedure

  • Contract details notice contractContract details noticeUK7Contract details notice on Find a Tender
  • Contract details notice contractContract details noticeUK7Contract details notice on Find a Tender
  • Contract award notice awardContract award noticeUK6Contract award notice on Find a Tender
  • Contract award notice awardContract award noticeUK6Contract award notice on Find a Tender
  • Tender notice tenderTender noticeUK4Tender notice on Find a Tender
  • Tender notice tenderTender noticeUK4Tender notice on Find a Tender